Faculty profile

Mustapha Tehfe

Back to faculty

ProfessorDépartement de médecineUniversité de Montréal

Mustapha Tehfe

Professor

Département de médecine

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
16 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

1,112

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile Google Scholar ResearchGate iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their Université de Montréal profile.

Latest papers

Neoadjuvant Chemotherapy-Immunotherapy in Non-Small Cell Lung Cancer: Can Positron Emission Tomography Scan Predict Complete Pathologic Response?
The Annals of thoracic surgery · 2026
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2025
Current Oncology · 2026
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma
Nature Communications · 2026

All 26 publications

26 publications.

Neoadjuvant Chemotherapy-Immunotherapy in Non-Small Cell Lung Cancer: Can Positron Emission Tomography Scan Predict Complete Pathologic Response?

Seitlinger J, Salko O, Bulgarelli Maqueda L, Meng A, Têtu M, Desilets A, Owen S, Shieh B, Wong A, Ofiara L, Agulnik J, Fiset PO, Malo J, Blais N, Florescu M, Tehfe M, Ferraro P, Nasir B, Cools-Lartigue J, Najmeh S, Juneau D, Elkrief A, Ferri L, Routy B, Liberman M, Spicer JD

The Annals of thoracic surgery20265 citations

DOI: 10.1016/j.athoracsur.2025.09.051 PMID: 41167577

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2025

Ahmed A, Mercier SL, Ramjeesingh R, Thompson R, Bastin DJ, Spadafora S, Megid TBC, Djedovic V, Taggar AS, Falkson C

Current Oncology20261 citationsOpen Access

DOI: 10.3390/curroncol33040228

DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma

Renouf DJ, Topham JT, Loree JM, Schaeffer DF, Knox JJ, Kavan P, Jonker D, Welch S, Couture F, Lemay F

Nature Communications2026Open Access

DOI: 10.1038/s41467-026-70120-z

Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Topham JT, Beckmann HM, Karasinska JM, Loree JM, Knox JJ, Kavan P, Jonker D, Welch S, Couture F, Lemay F

Clinical Cancer Research2026Open Access

DOI: 10.1158/1078-0432.ccr-26-0793

Clinical Utility of Liquid Biopsy for the Early Diagnosis of EGFR-Mutant Advanced Lung Cancer Patients in a Real-Life Setting (CLEAR Study).

Samaha R, El Sayed R, Alameddine R, Florescu M, Tehfe M, Routy B, Elkrief A, Belkaid W, Desilets A, Weng X, Nassabein R, Blanc-Durand F, Kenth G, Kasymjanova G, Agulnik J, Blais N

Current oncology (Toronto, Ont.)20255 citationsOpen Access

DOI: 10.3390/curroncol32020057 PMID: 39996857

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.

Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K

Journal of clinical oncology : official journal of the American Society of Clinical Oncology2024246 citationsOpen Access

DOI: 10.1200/jco.23.01601 PMID: 38382001

CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC.

Desilets A, Pinheiro G, Belkaid W, Salko O, Malo J, Zarour E, Jouquan A, Thibaudeau AJ, Nolin MA, Stagg J, Florescu M, Tehfe M, Blais N, Tabchi S, Chalaoui J, Stephenson P, Elkrief A, Trinh VQ, Routy B, Liberman M

JTO clinical and research reports20247 citationsOpen Access

DOI: 10.1016/j.jtocrr.2024.100737 PMID: 39624249

Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E.

Chen EX, Kavan P, Tehfe M, Kortmansky JS, Sawyer MB, Chiorean EG, Lieu CH, Polite B, Wong L, Fakih M, Spencer K, Chaves J, Li C, Leconte P, Adelberg D, Kim R

Clinical colorectal cancer2024

DOI: 10.1016/j.clcc.2024.03.002 PMID: 38653648

Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma.

Ma LX, Wang Y, Espin-Garcia O, Allen MJ, Jang GH, Zhang A, Dodd A, Ramotar S, Hutchinson S, Tehfe M, Ramjeesingh R, Biagi J, Wilson JM, Notta F, Fischer SE, Zogopoulos G, Gallinger S, Grant RC, Khokha R, Chan N, Grünwald BT, Knox JJ, O'Kane GM

British journal of cancer202325 citationsOpen Access

DOI: 10.1038/s41416-023-02214-0 PMID: 36927977

The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.

Proulx-Rocray F, Routy B, Nassabein R, Belkaid W, Tran-Thanh D, Malo J, Tonneau M, Ouarzadi OE, Florescu M, Tehfe M, Blais N

Cancer treatment and research communications202323 citationsOpen Access

DOI: 10.1016/j.ctarc.2023.100767 PMID: 37832364

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Mustapha Tehfe

Research

Latest papers

Neoadjuvant Chemotherapy-Immunotherapy in Non-Small Cell Lung Cancer: Can Positron Emission Tomography Scan Predict Complete Pathologic Response?

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2025

DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma

Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Clinical Utility of Liquid Biopsy for the Early Diagnosis of EGFR-Mutant Advanced Lung Cancer Patients in a Real-Life Setting (CLEAR Study).

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.

CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC.

Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E.

Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma.

The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.

Frequent collaborators

Normand Blais

Bertrand Routy

Arielle Elkrief

Danh Tran-Thanh

Derek Jonker

Dongsheng Tu

Brandon Meyers

Jonathan Loree

Stephen Welch

Francine Aubin

Philip Wong

Houda Bahig

Elena Elimova

George Zogopoulos

Jean Chalaoui

Édith Filion

Louise Lambert

David Roberge

Louis Gaboury

Charles Leduc

Philippe Stephenson

Roula Albadine

Olivier Boucher

Tareck Ayad

Olivier Ballivy

Shivani Dadwal

Danielle Charpentier

Lorenzo Ferri

Rama Khokha

Steven Gallinger

Gerald Batist

Rakesh Goel

Osvaldo Espin Garcia